Publications

1. GVS advice Vocabria® and Rekambys® for the treatment of HIV-1 infection

   The National Health Care Institute has completed its assessment whether the products Rekambys® and Vocabria® can be included in ...

   Report | 08-06-2021

2. Package advice isatuximab (Sarclisa®) for the treatment of multiple myeloma

   The National Health Care Institute has completed its assessment whether isatuximab (Sarclisa®) in combination with carfilzomib ...

   Report | 25-05-2021

3. GVS advice ivacaftor (Kalydeco®) extension of further conditions

   Zorginstituut Nederland carried out a review to extend the further conditions for reimbursement of ivacaftor (Kalydeco®). The ...

   Report | 25-05-2021

4. GVS advice dapagliflozin (Forxiga®) extension of further condition

   The National Health Care Institute has completed its assessment whether the further condition of dapagliflozin (Forxiga®) could ...

   Report | 12-05-2021

5. Package advice pertuzumab and trastuzumab (Phesgo®) for the treatment of breast cancer

   Zorginstituut Nederland has completed its assessment whether the fixed combined dose of pertuzumab and trastuzumab (Phesgo®) can ...

   Report | 11-05-2021

6. Package advice onasemnogene abeparvovec (Zolgensma®) for the treatment of SMA

   Zorginstituut Nederland has completed its assessment whether onasemnogene abeparvovec (Zolgensma®) for the treatment of patients ...

   Report | 06-05-2021

7. GVS advice inclisiran (Leqvio®) for the treatment of hypercholesterolemia

   The National Health Care Institute has completed its assessment whether inclisiran (Leqvio®) is interchangeable with a product ...

   Report | 04-05-2021

8. Advice on the clustering of combination products and ghost clusters in GVS (part 1)

   The Minister of Medical Care has asked Zorginstituut Nederland questions about the clustering of two categories of medicinal ...

   Report | 04-05-2021

9. GVS advice elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in combination with ivacaftor (Kalydeco®)

   The National Health Care Institute has completed its assessment whether elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in ...

   Report | 29-04-2021

10. GVS assessment of trientine dihydrochloride (Cufence®) for the treatment of Wilson’s disease

    The National Health Care Institute has completed its assessment whether trientine dihydrochloride (Cufence®) can be included in ...

    Report | 19-04-2021